PharmacoEconomics Italian Research Articles

, Volume 10, Issue 1, pp 23–35

Analisi di costo-efficacia della vaccinazione universale in Italia con il vaccino Rix4414 contro i rotavirus

  • B. Standaert
  • A. Marocco
  • B. Assael
  • G. Gabutti
  • A. Guarino
  • P. L. Lopalco
  • Federico Marchetti
  • F. M. Ruggeri
  • L. Titone
  • A. Tozzi
  • G. Vitali Rosati
  • C. Zotti
  • E. Franco
Article

DOI: 10.1007/BF03320638

Cite this article as:
Standaert, B., Marocco, A., Assael, B. et al. Pharmacoeconomics-Ital-Res-Articles (2008) 10: 23. doi:10.1007/BF03320638

Cost-effectiveness of universal rotavirus vaccination with Rix4414 in Italy

Summary

Objectives: Rotavirus (RV) is the most common etiological agent of gastroenteritis in children. The oral vaccine Rix4414 was recently commercialized in Italy for prevention of RV infections. The health outcomes and the economic impact of a national RV immunization program were assessed.

Design: A Markov model simulated the flow of a birth cohort on RV disease burden and costs up to age 5, comparing a RV vaccination programme with no vaccination. Lifetime cost-effectiveness for the national healthcare system (NHS) and the society (S) with a benchmark of 50,000 €/QALY was analysed.

Main results: Disease’s medical direct costs exceeded 30 million €/year, while indirect costs approached 112 million €/year. A routine, universal RV immunization program, for a birth cohort of 550,000 children, would prevent 80% of RV diarrhoea, 97% of severe RV cases, 87% of medical consultations and 98% of hospitalizations. In the NHS perspective, the incremental cost/QALY would be € 14,829 and it would decrease to € −17,030 (cost-saving) in the S perspective. In the private market scenario, the incremental cost/QALY (€ 24,687) would remain far below the threshold.

Conclusion: A national immunization program with Rix44141 in Italy would be cost-effective both from the S and the NHS perspective.

Copyright information

© Adis Data Information 2008

Authors and Affiliations

  • B. Standaert
    • 1
  • A. Marocco
    • 2
  • B. Assael
    • 3
  • G. Gabutti
    • 4
  • A. Guarino
    • 5
  • P. L. Lopalco
    • 6
  • Federico Marchetti
    • 2
  • F. M. Ruggeri
    • 7
  • L. Titone
    • 8
  • A. Tozzi
    • 9
  • G. Vitali Rosati
    • 10
  • C. Zotti
    • 11
  • E. Franco
    • 12
  1. 1.Health-Economics DepartmentGlaxoSmithKline BiologicalsRixensartBelgio
  2. 2.Direzione MedicaGlaxoSmithKline S.p.AVeronaItalia
  3. 3.Ospedale Regionale Fibrosi CisticaVeronaItalia
  4. 4.Dipartimento di Medicina Clinica e SperimentaleUniversità di FerraraItalia
  5. 5.Dipartimento di PediatriaUniversità di NapoliItalia
  6. 6.Dipartimento di Sanità PubblicaUniversità di BariItalia
  7. 7.Dipartimento di Sanità Alimentare e AnimaleIstituto Superiore di SanitàRomaItalia
  8. 8.Istituto di Malattie InfettiveUniversità di PalermoItalia
  9. 9.Unità di EpidemiologiaOspedale Bambin GesùRomaItalia
  10. 10.Pediatra di famigliaFirenzeItalia
  11. 11.Dipartimento di Sanità PubblicaUniversità di TorinoItalia
  12. 12.Dipartimento di Sanità PubblicaUniversità di Roma Tor VergataItalia

Personalised recommendations